

Retail Research	IPO Note
Sector: Pharmaceutical Sector	Price Band (Rs): 705 - 741
4 th August 2023	Recommendation: Subscribe for long term Horizon

Concord Biotech Limited

Company Overview:

Concord Biotech is an India-based biopharma company, globally recognized for the expertise in developing and manufacturing fermentation-based APIs in the fields of immunosuppressants and oncology. According to the F&S Report of FY22, they held a significant market share of over 20% by volume, supplying to more than 70 countries, including major regulated markets such as the United States, Europe, Japan, and India. Their identified fermentation-based API products include mupirocin, sirolimus, tacrolimus, mycophenolate sodium, and cyclosporine. They ventured into the formulation business in India and emerging markets like Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore, and Paraguay in 2016. Over time, they have further expanded their reach to include the United States.

Key Highlights:

Robust Product Portfolio: As of March'23, the company has 23 API products. The company had filed 128 Drug Master Files (DMFs) across several countries for the APIs, including 20, 65 and 4, respectively, in the United States, Europe and Japan, as of June'23. In addition, they had obtained Certification of Suitability to the Monographs of the European Pharmacopoeia (CEPs) for 14 APIs as of March'23. In India, they market a portfolio of 27 brands across immunosuppressants, nephrology drugs, and anti-infective drugs for critical care. They also have 77 approved products for formulations as well.

Manufacturing Facility: As of March'23, they have 3 manufacturing facilities in Gujarat comprising API manufacturing facilities in Dholka and Limbasi, and a formulation manufacturing facility in Valthera. The total annual installed fermentation capacity for APIs is 1,250 m3. Dholka and Limbasi facilities have 41 blocks, and 387 reactors for flexible plant configuration. Valthera formulation facility has an annual installed production capacity of 801.64 million units, with dosage capability per shift of 0.45 million tablets, 0.36 million capsules, and 646.46 bottles of dry syrup.

Customer base: Customers: As of March'23, the Company has over 200 customers in 70+ countries for their APIs and formulations. They have also entered into long-term supply agreements with some customers. Some of the key API customers include Intas Pharmaceuticals Limited and Glenmark Pharmaceuticals Limited. The company has on average 8 years of relationships with top ten revenue customers as of FY23.

Valuation:

At CMP, the business is valued at a FY23 Post issue P/E multiple of 32.3 times at upper price band. The IPO looks fairly valued across various valuation parameters when compared with its close peers. Investors can SUBSCRIBE the issue for long term investment perspective.

Issue Details	
Date of Opening	4 th August 23
Date of Closing	8 th August 23
Price Band (Rs)	705 – 741
Issue Size (Rs cr)	1,475 – 1,551
No. of shares	2,09,25,652
Face Value (Rs)	1
Post Issue Market Cap (Rs cr)	7,375 – 7,752
BRLMs	Kotak Mahindra Capital, Citi Group Global Market, Jefferies India
Registrar	Link Intime Private Limited
Bid Lot	20 shares and in multiple thereof
QIB shares	50%
Retail shares	35%
NIB (HNI) shares	15%
Employee Reservation	Upto 10,000 Equity shares
Employee Price Band (Rs)	635 - 671

Objects of Issue	
	(Rs Cr.)
Gross Proceed From OFS	1,551
(Less) Offer expenses in relation to the OFS*	-
Net Proceeds*	-

*The net proceed will be received by the selling shareholders, in proportion to the offered shares sold by the respective selling shareholders as part of the offer.

Shareholding Pattern		
Pre Issue	No. of Shares	%
Promoter & Promoter Group	31,64,64,857	79.0
Public & Others	8,41,23,583	21.0
Total	40,05,88,440	100.0

Post Issue @Lower Price Band	No. of Shares	%
Promoter & Promoter Group	30,64,50,146	76.5
Public & Others	9,41,38,294	23.5
Total	40,05,88,440	100.0

Post Issue @Upper Price Band	No. of Shares	%
Promoter & Promoter Group	30,64,50,146	76.5
Public & Others	9,41,38,294	23.5
Total	40,05,88,440	100.0

Source: RHP, SSL Research

Risk factors

- Any delay, interruption or reduction in the supply of the raw materials or the transportation of the raw materials or products may adversely impact the pricing and supply of the products and have an adverse effect on the business.
- Any manufacturing or quality control issues may damage the reputation, subject to regulatory action, and expose them to litigation or other liabilities, which could adversely affect the business, financial condition and results of operations.
- A slowdown or shutdown in the manufacturing or research and development operations, all located in Gujarat, India, could adversely affect the business, financial condition and results of operations.
- The company depends on a limited number of customers for a substantial portion of the revenues. Any significant reduction in demand for the products from such customers may adversely affect the business and results of operations.
- Any inability to accurately forecast demand for the products, managing of the inventory, and utilization of the manufacturing capacity optimally may have an adverse effect on the business, financial condition, results of operations, and cash flows.

Growth strategy

- Continue to increase the API market share and further develop the portfolio of complex and niche APIs with high growth potential.
- Increase the presence of the existing formulations and expand into new formulations.
- Improve cost management and operational efficiencies.
- Grow the CDMO business.

Revenue Break-up (Rs cr)

Particulars	FY21		FY22		FY23	
	Revenue (Rs cr)	% to Total	Revenue (Rs cr)	% to Total	Revenue (Rs cr)	% to Total
India	252.7	41.0%	337.4	47.3%	432.1	50.7%
America	159.8	25.9%	131.5	18.4%	147.3	17.3%
Rest of the World	204.5	33.2%	244.1	34.2%	273.8	32.1%
Total	616.9	100.0%	712.9	100.0%	853.2	100.0%

Source: RHP, SSL Research


Particulars	FY21		FY22		FY23	
	Revenue (Rs cr)	% to Total	Revenue (Rs cr)	% to Total	Revenue (Rs cr)	% to Total
API	506.9	82.2%	574.9	80.6%	761.3	89.2%
Formulations	110.1	17.8%	138.0	19.4%	91.9	10.8%
Total	616.9	100.0%	712.9	100.0%	853.2	100.0%

Source: RHP, SSL Research

Industry Overview

Global API Market Size: High Drug Demand Will Continue to Drive Growth in the API Market


The global API market was valued at approximately USD 219 bn (Rs 18,157 bn) in FY22, which constitutes about 16% of the total pharmaceutical formulations market and is expected to reach approximately USD 278 bn (Rs 23,051 bn) by the year FY26, at a projected CAGR of 6.1% over the forecast period of FY22 to FY26. Of the total market, biological APIs accounted for 37% of the share in FY22, and small molecule drug APIs accounted for the remainder of 63% share.



Source: RHP, SSL Research

India API Market

The total domestic India API market (APIs consumed for exported and domestically consumed formulations) is expected to grow at a CAGR of 11.1% between 2022 and 2026. The API consumption for domestic formulations is also expected to drive high demand in the next four to five years. This growth is in line with the overall growth of pharmaceutical drug consumption in the country. As disease patterns shift from acute to chronic and translate into high drug (and API) volume consumption, access to healthcare facilities and affordable medicine increases, and economic prosperity grows, the growth of the API industry is projected to follow suit.



Source: RHP, SSL Research

Financial Snapshot

Concord Biotech Limited			
(Rs. Cr.)	Pre Issue	Post Issue	
	FY22	FY23	
Particulars		Price Band	
	741.0	705.0	741.0
Net Sales	712.9	853.2	853.2
Total Income	736.3	888.5	888.5
EBIDTA	269.6	345.2	345.2
PAT	174.9	240.1	240.1
Equity Share Capital	9.5	10.5	10.5
No of Equity Shares	9.5	10.5	10.5
Face Value	1.0	1.0	1.0
EPS	18.4	22.9	22.9
CMP	741.0	705.0	741.0
Cash and Bank	88.9	43.4	43.4
Debt	60.6	31.2	31.2
Market Cap	7,047.7	7,375.7	7,752.3
BV per share (Rs)	116.0	132.9	132.9
PE(x)	40.3	30.7	32.3
P/BV (x)	6.4	5.3	5.6
Enterprise Value	7,019.3	7,363.5	7,740.1
Mcap/Sales (x)	9.9	8.6	9.1
EV/Sales (x)	9.8	8.6	9.1
EV/EBIDTA (x)	26.0	21.3	22.4
EBITDA Margins (%)	37.8	40.5	40.5
Net Margins (%)	24.5	28.1	28.1
ROE (%)	16.6	19.3	19.3
ROCE (%)	21.6	25.3	25.3
Debt/Equity	0.1	0.0	0.0
Net worth	1,103.2	1,390.0	1,390.0

Source: RHP, SSL Research (Post Issue)

Year	FY20	FY21	FY22
Net Sales	616.9	712.9	853.17
EBITDA	327.1	269.6	345.2
Net Profit	234.9	174.9	240.08
EBITDA Margin (%)	53.0	37.8	40.5
Net Profit Margin (%)	38.1	24.5	28.1

Source: RHP, SSL Research

Peer Comparison

	Concord Biotech Ltd	Divi's Laboratories Ltd	Suven Pharmaceuticals Ltd	Lauras Labs Ltd
CMP	741.0	3726.3	489.1	384.4
Sales (Rs cr)	853.2	7768.0	1340.0	5773.0
EBITDA (Rs cr)	345.2	2368.0	567.0	1482.0
Net Profit (Rs cr)	240.1	1823.0	411.0	760.0
M.Cap (Rs Cr)	7752.3	98921.6	12450.8	20703.1
EBITDA Margin (%)	40.5	30.5	42.3	25.7
PE(x)	32.3	54.3	30.3	36.7
RoE (%)	19.3	14.9	25.2	20.4
RoCE (%)	25.3	19.3	33.0	22.2

(Source: RHP, SSL Research)

CMP as of 3rd August, 2023

The data is based on FY23 financial data

SBICAP Securities Limited

(CIN): U65999MH2005PLC155485

SEBI Registration No.: Stock Broker: INZ000200032 | DP Registration No.: IN-DP-314-2017| Research Analyst : INH000000602

Portfolio Manager: INP000004912 | IRDA : CA0103 | PFRDA Registration No: POP 26092018

Registered & Corporate Office: Marathon Futurex, Unit No. 1201, B-Wing, 12th Floor, N M Joshi Marg,

Mafatlal Mill Compound, Lower Parel East, Mumbai 400013

For any information contact us: (022) 6854 5555**E-mail: helpdesk@sbicapsec.com I Web: www.sbisecurities.in****DISCLOSURES & DISCLAIMERS:**

Analyst Certification: The views expressed in this research report ("Report") accurately reflect the personal views of the research analysts ("Analysts") employed by SBICAP Securities Limited (SSL) about any and all of the subject issuer(s) or company(ies) or securities. This report has been prepared based upon information available to the public and sources, believed to be reliable. I/We also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

The Analysts engaged in preparation of this Report or his/her relative:-

(a) do not have any financial interests in the subject company mentioned in this Report; (b) do not own 1% or more of the equity securities of the subject company mentioned in the report as of the last day of the month preceding the publication of the research report; (c) do not have any material conflict of interest at the time of publication of the Report.

The Analysts engaged in preparation of this Report:-

(a) have not received any compensation from the subject company in the past twelve months; (b) have not managed or co-managed public offering of securities for the subject company in the past twelve months; (c) have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months; (d) have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months; (e) has not received any compensation or other benefits from the subject company or third party in connection with the Report; (f) has not served as an officer, director or employee of the subject company; (g) is not engaged in market making activity for the subject company.

Name	Qualification	Designation
Sudeep Shah	MMS-Finance	DVP- Technical & Derivative Research
Sunny Agrawal	B.E, MBA (Finance)	DVP - Fundamental Research
Rajesh Gupta	PGDBM (Finance), MA (Bus. Eco)	AVP - Fundamental Research
Monica Chauhan	C.A.	Research Analyst - Equity Fundamentals
Harsh Vasa	C.A.	Research Analyst - Equity Fundamentals
Gautam Updhyaya	MBA (Finance)	Research Analyst - Equity Derivatives
Netra Deshpande	MMS (Finance)	Sr. Research Analyst - Currency & Commodity
Vinayak Gangule	BE (IT)	Research Analyst - Equity Technicals
Pratik Patni	BSc (Biotech Entire)	Research Analyst- Equity Derivatives
Amit Chawda	Bcom	Research Analyst - Equity Technicals
Kalpesh Mangade	B.Com	MIS Analyst - Retail Research

Other Disclosures :

SBICAP Securities Limited ("SSL") a is a company engaged in diversified financial services business including securities broking, DP services,, distribution of Mutual Fund, insurance products and other financial products. SSL is a member of Stock Exchange(s). SSL is also a Depository Participant registered with NSDL & CDSL. SSL is a large broking house catering to retail, HNI and institutional clients. It operates through its branches and authorized persons spread across the country and the clients are provided online trading through internet and offline trading through branches and call & trade facility. SSL is a wholly owned subsidiary of SBI Capital Markets Limited ("SBICAP"), which is engaged into investment banking, project advisory and financial services activities and is registered with the Securities and Exchange Board of India as a "Category I" Merchant Banker. SBICAP is a wholly owned subsidiary of State Bank of India. Hence, State Bank of India and all its subsidiaries, including, SBICAP and banking subsidiaries are treated and referred to as Associates of SSL.

We hereby declare that our activities were neither suspended nor we have materially defaulted with any stock exchange authority with whom we are registered in last five years. However SEBI, Exchanges and Depositories have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty for certain procedural lapses. We have not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point of time.

SSL or its Associates, may: (a) from time to time, have long or short position in, and buy or sell the securities of the company mentioned in the Report or (b) be engaged in any other in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company discussed herein or act as an advisor or lender/borrower to such company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions (c) have any financial interests in the subject company mentioned in this Report (d) be engaged in market making activity for the subject company.

SSL does not have actual / beneficial ownership of one percent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the Report. However, since Associates of SSL are engaged in the financial services business, they might have in their normal course of business financial interests or actual / beneficial ownership of one percent or more in various companies including the subject company mentioned herein this Report.

SSL or its Associates might have managed or co-managed public offering of securities for the subject company in the past twelve months and might have received compensation from the companies mentioned in the Report during the period preceding twelve months from the date of this Report for services in respect of managing or co-managing public offerings/corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction.

Compensation paid to Analysts of SSL is not based on any specific merchant banking, investment banking or brokerage service transaction.

SSL or its Associate did not receive any compensation or any benefit from the subject company or third party in connection with preparation of this Report.

This Report is for the personal information of the authorized recipient(s) and is not for public distribution and should not be reproduced, transmitted or redistributed to any other person or in any form without SSL's prior permission. The information provided in the Report is from publicly available data, which we believe, are reliable. While reasonable endeavors have been made to present reliable data in the Report so far as it relates to current and historical information, but SSL does not guarantee the accuracy or completeness of the data in the Report. Accordingly, SSL or any of its Associates including directors and employees thereof shall not be in any way responsible or liable for any loss or damage that may arise to any person from any inadvertent error in the information contained, views and opinions expressed in this Report or in connection with the use of this Report.

Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian securities market.

The projections and forecasts described in this Report should be carefully evaluated as these :

1. Are based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies.
2. Can be expected that some of the estimates on which these were based, will not materialize or will vary significantly from actual results, and such variances may increase over time.
3. Are not prepared with a view towards compliance with published guidelines or generally accepted accounting principles. No independent accountants have expressed an opinion or any other form of assurance on these.
4. Should not be regarded, by mere inclusion in this report, as a representation or warranty by or on behalf of SSL the authors of this report, or any other person, that these or their underlying assumptions will be achieved.

This Report is for information purposes only and SSL or its Associates accept no liabilities for any loss or damage of any kind arising out of the use of this report. Though disseminated to recipients simultaneously, not all recipients may receive this report at the same time. SSL will not treat recipients as clients by virtue of their receiving this report. It should not be construed as an offer to sell or solicitation of an offer to buy, purchase or subscribe to any securities this report shall not form the basis of or be relied upon in connection with any contract or commitment, whatsoever. This report does not solicit any action based on the material contained herein.

It does not constitute a personal recommendation and does not take into account the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The securities discussed in this Report may not be suitable for all the investors. SSL does not provide legal, accounting or tax advice to its clients and you should independently evaluate the suitability of this Report and all investors are strongly advised to seek professional consultation regarding any potential investment.

Certain transactions including those involving futures, options, and other derivatives as well as non-investment grade securities give rise to substantial risk and are not suitable for all investors. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment.

The price, value and income of the investments referred to in this Report may fluctuate and investors may realize losses on any investments. Past performance is not a guide for future performance. Actual results may differ materially from those set forth in projections. SSL has reviewed the Report and, the current or historical information included here is believed to be reliable, the accuracy and completeness of which is not guaranteed. SSL does not have any obligation to update the information discussed in this Report.

The opinions expressed in this report are subject to change without notice and SSL or its Associates have no obligation to tell the clients when opinions or information in this report change. This Report has not been approved and will not or may not be reviewed or approved by any statutory or regulatory authority in India, United Kingdom or Singapore or by any Stock Exchange in India, United Kingdom or Singapore. This report may not be all inclusive and may not contain all the information that the recipient may consider material.

The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this Report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. Distributing /taking/sending/dispatching/transmitting this document in certain foreign jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Failure to comply with this restriction may constitute a violation of laws in that jurisdiction.

Legal Entity Disclosure

Singapore: This Report is distributed in Singapore by SBICAP (Singapore) Limited (Registration No. 201026168R), an Associate of SSL incorporated in Singapore. SBICAP (Singapore) Limited is regulated by the Monetary Authority of Singapore as a holder of a Capital Markets Services License and an Exempt Financial Adviser in Singapore. SBICAP (Singapore) Limited's services are available solely to persons who qualify as Institutional Investors or Accredited Investors (other than individuals) as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and this Report is not intended to be distributed directly or indirectly to any other class of persons. Persons in Singapore should contact SBICAP (Singapore) Limited in respect of any matters arising from, or in connection with this report via email at singapore.sales@sbicap.sgor by call at +65 6709 8651.